Form 8-K - Current report:
SEC Accession No. 0001193125-25-146135
Filing Date
2025-06-25
Accepted
2025-06-25 07:12:53
Documents
14
Period of Report
2025-06-25
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d89458d8k.htm   iXBRL 8-K 30235
2 EX-99.1 d89458dex991.htm EX-99.1 14408
6 GRAPHIC g89458g0625072647479.jpg GRAPHIC 3519
  Complete submission text file 0001193125-25-146135.txt   171169

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20250625.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20250625_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20250625_pre.xml EX-101.PRE 11264
16 EXTRACTED XBRL INSTANCE DOCUMENT d89458d8k_htm.xml XML 3646
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 251070870
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)